Drug Combination Details
| General Information of the Combination (ID: C53650) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Anti-PD-1 antibody Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | F2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MDC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TGFB1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | ||
| CSQT-2 | CVCL_M183 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Hep3B cells was subcutaneously injected into the left axilla of each five-week-old healthy BALB/c female nude mice. | |||||
| Experimental
Result(s) |
Curcumin had a synergistic effect with anti-PD-1 to slow Hep3B cell proliferation, activate lymphocytes, inhibit immune evasion, and down-regulate TGF-beta1 expression. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci. 2021 Mar 19;279:119359. | |||
